739 related articles for article (PubMed ID: 15220008)
1. Pharmacotherapeutic approaches to the treatment of Alzheimer's disease.
Standridge JB
Clin Ther; 2004 May; 26(5):615-30. PubMed ID: 15220008
[TBL] [Abstract][Full Text] [Related]
2. Contemporary issues in the treatment of Alzheimer's disease: tangible benefits of current therapies.
Tariot PN
J Clin Psychiatry; 2006; 67 Suppl 3():15-22; quiz 23. PubMed ID: 16649847
[TBL] [Abstract][Full Text] [Related]
3. Rationalizing therapeutic approaches in Alzheimer's disease.
Grossberg GT
CNS Spectr; 2005 Nov; 10(11 Suppl 18):17-21. PubMed ID: 16273026
[TBL] [Abstract][Full Text] [Related]
4. Treatment of Alzheimer's disease in the long-term-care setting.
Smith DA
Am J Health Syst Pharm; 2009 May; 66(10):899-907. PubMed ID: 19420308
[TBL] [Abstract][Full Text] [Related]
5. Paradigm shift in NMDA receptor antagonist drug development: molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer's disease and other neurologic disorders.
Lipton SA
J Alzheimers Dis; 2004 Dec; 6(6 Suppl):S61-74. PubMed ID: 15665416
[TBL] [Abstract][Full Text] [Related]
6. Pharmacotherapeutic strategies in the treatment of severe Alzheimer's disease.
Deardorff WJ; Grossberg GT
Expert Opin Pharmacother; 2016 Sep; 17(13):1789-800. PubMed ID: 27450461
[TBL] [Abstract][Full Text] [Related]
7. Ginkgo biloba Extract (EGb761), Cholinesterase Inhibitors, and Memantine for the Treatment of Mild-to-Moderate Alzheimer's Disease: A Network Meta-Analysis.
Thancharoen O; Limwattananon C; Waleekhachonloet O; Rattanachotphanit T; Limwattananon P; Limpawattana P
Drugs Aging; 2019 May; 36(5):435-452. PubMed ID: 30937879
[TBL] [Abstract][Full Text] [Related]
8. The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer's disease.
Thompson S; Lanctôt KL; Herrmann N
Expert Opin Drug Saf; 2004 Sep; 3(5):425-40. PubMed ID: 15335298
[TBL] [Abstract][Full Text] [Related]
9. Benefits of combined cholinesterase inhibitor and memantine treatment in moderate-severe Alzheimer's disease.
Gauthier S; Molinuevo JL
Alzheimers Dement; 2013 May; 9(3):326-31. PubMed ID: 23110864
[TBL] [Abstract][Full Text] [Related]
10. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial.
Porsteinsson AP; Grossberg GT; Mintzer J; Olin JT;
Curr Alzheimer Res; 2008 Feb; 5(1):83-9. PubMed ID: 18288936
[TBL] [Abstract][Full Text] [Related]
11. A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer's disease.
Di Santo SG; Prinelli F; Adorni F; Caltagirone C; Musicco M
J Alzheimers Dis; 2013; 35(2):349-61. PubMed ID: 23411693
[TBL] [Abstract][Full Text] [Related]
12. EFNS-ENS/EAN Guideline on concomitant use of cholinesterase inhibitors and memantine in moderate to severe Alzheimer's disease.
Schmidt R; Hofer E; Bouwman FH; Buerger K; Cordonnier C; Fladby T; Galimberti D; Georges J; Heneka MT; Hort J; Laczó J; Molinuevo JL; O'Brien JT; Religa D; Scheltens P; Schott JM; Sorbi S
Eur J Neurol; 2015 Jun; 22(6):889-98. PubMed ID: 25808982
[TBL] [Abstract][Full Text] [Related]
13. [Glutamate-related excitotoxicity neuroprotection with memantine, an uncompetitive antagonist of NMDA-glutamate receptor, in Alzheimer's disease and vascular dementia].
Tanović A; Alfaro V
Rev Neurol; 2006 May 16-31; 42(10):607-16. PubMed ID: 16703529
[TBL] [Abstract][Full Text] [Related]
14. What is the rationale for new treatment strategies in Alzheimer's disease?
Rogawski MA
CNS Spectr; 2004 Jul; 9(7 Suppl 5):6-12. PubMed ID: 15241294
[TBL] [Abstract][Full Text] [Related]
15. [Anti-Dementia Drugs (Anti-Alzheimer's Disease Drugs)].
Yamada M
Brain Nerve; 2023 May; 75(5):464-469. PubMed ID: 37194514
[TBL] [Abstract][Full Text] [Related]
16. Rationale for combination therapy with galantamine and memantine in Alzheimer's disease.
Grossberg GT; Edwards KR; Zhao Q
J Clin Pharmacol; 2006 Jul; 46(7 Suppl 1):17S-26S. PubMed ID: 16809811
[TBL] [Abstract][Full Text] [Related]
17. Pathologically-activated therapeutics for neuroprotection: mechanism of NMDA receptor block by memantine and S-nitrosylation.
Lipton SA
Curr Drug Targets; 2007 May; 8(5):621-32. PubMed ID: 17504105
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and tolerability of memantine in the treatment of dementia.
Rossom R; Adityanjee ; Dysken M
Am J Geriatr Pharmacother; 2004 Dec; 2(4):303-12. PubMed ID: 15903287
[TBL] [Abstract][Full Text] [Related]
19. [Efficacy of memantine in the treatment of Alzheimer's disease].
Molinuevo Guix JL; Lladó Plarrumaní A
Neurologia; 2005 Dec; 20(10):686-91. PubMed ID: 16317590
[TBL] [Abstract][Full Text] [Related]
20. AChE Inhibitors and NMDA Receptor Antagonists in Advanced Alzheimer's Disease.
Glynn-Servedio BE; Ranola TS
Consult Pharm; 2017 Sep; 32(9):511-518. PubMed ID: 28855009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]